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Abstract
Tumor necrosis factor alpha (TNF-a) is a major inflammatory mediator that exhibits actions leading to tissue destruction and
hampering recovery from damage. At present, two antibodies against human TNF-a (hTNF-a) are available, which are widely
used for the clinic treatment of certain inflammatory diseases. This work was undertaken to identify a novel functional
epitope of hTNF-a. We performed screening peptide library against anti-hTNF-a antibodies, ELISA and competitive ELISA to
obtain the epitope of hTNF-a. The key residues of the epitope were identified by means of combinatorial alanine scanning
and site-specific mutagenesis. The N terminus (80–91 aa) of hTNF-a proved to be a novel epitope (YG1). The two amino
acids of YG1, proline and valine, were identified as the key residues, which were important for hTNF-a biological function.
Furthermore, the function of the epitope was addressed on an animal model of collagen-induced arthritis (CIA). CIA could
be suppressed in an animal model by prevaccination with the derivative peptides of YG1. The antibodies of YG1 could also
inhibit the cytotoxicity of hTNF-a. These results demonstrate that YG1 is a novel epitope associated with the biological
function of hTNF-a and the antibodies against YG1 can inhibit the development of CIA in animal model, so it would be a
potential target of new therapeutic antibodies.
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Introduction
Tumor necrosis factor alpha (TNF-a) is an inflammatory
cytokine primarily secreted by the macrophages/monocytes in
response to a variety of stresses that interfere drastically with the
growth, differentiation, and death of both immune and nonim-
mune cell types, and simultaneously stimulate a series of other
proinflammatory mediators [1]. TNF-a is initially synthesized as
cell surface-bound precursor transmembrane TNF (tmTNF, a
homotrimer of 26-kDa monomers), then cleaved to the soluble-
form TNF-a (sTNF, a monomer of 17 kDa) by TNF-alpha-
converting enzyme (TACE). Both sTNF and tmTNF ligands
interact with either of 2 distinct receptors—TNF receptor 1
(TNFR1, p55, CD120a) and TNF receptor 2 (TNFR2, p75,
CD120b)—on a wide variety of cell types to mediate their
biological functions [2,3].
Rheumatoid arthritis (RA) is a systemic, progressive, inflamma-
tory, autoimmune disorder that targets primarily the synovial
tissues and leads to destruction of cartilage and ultimately bone.
The conventional disease-modifying anti-rheumatic drugs
(DMARDs) can efficiently improve sign and symptoms and
increase functional ability. However, they can do little on halting
progressive joint damage. The breakthrough in development of
biological agents for the treatment of RA was to target the immune
system, which was ascribed to new insight into the major biological
function of TNF-a in joint inflammation and destruction. The
three currently available TNF antagonists, adalimumab, a fully
human monoclonal antibody; infliximab, a chimeric monoclonal
antibody; and etanercept, a soluble receptor construct, have
changed the course and face of rheumatoid arthritis and
consequently the outcomes for patients and society, especially in
combination with methotrexate [3–5]. Although the potential risks
of infection, lymphoma, solid tumor and congestive heart failure
would increase when these TNF-a antagonists are used in clinical
applications[6–8], efficacy and safety of the treatments are
validated in large clinical cases, especially in those which do not
respond to traditional treatments[9,10].
In this study, we identified a novel precise epitope of hTNF-a,
which could not be recognized by those commercial antibodies.
Moreover, we found that antibodies induced by the derivative
peptides of this epitope could suppress the cytotoxicity of hTNF-a
and the development of collagen-induced arthritis (CIA) in an
animal model of RA. Thus, this epitope is a potential new target
for the development of TNF-a blockade agents.
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Identification of the hTNF-a Mimotope and Epitope
Polyclonal antibodies against rhTNF-a were prepared and
purified as described in ‘‘Materials and methods’’. The phage
clones were isolated by incubating the 12-mer linear random
peptide library with the antibodies after 3 rounds of bioscreening.
Competitive enzyme-linked immunosorbent assay (ELISA) was
employed to select 12 positive phage clones(Figure 1A), and the
selected clones were then sequenced. The sequencing result
showed that eight different sequences were captured, then the
sequence identity between these binding peptides and hTNF-a
was analyzed. We found that the sequences of all the selected
peptides were similar to the sequence of amino acids 80–91 in
hTNF-a(Figure 1B). There were 5 clones with the same amino
acid sequence FHLTPSERPVEA in the selected 12 positive
clones. This sequence was with high similarity to the natural
residues 80–91 of human TNF, designated as 312. The peptide
Figure 1. Identification of the mimotope and epitope of hTNF-a.A :Specific phage clones binding to rhTNF-a antibodies were selected by
ELISA and competitive ELISA. 1–12 referred to different phage clones. White bars represent negative control, black bars represent screened phage
clones (1610
9) alone, and gray bars represent screened phage clones (1610
9) plus rhTNF-a protein (5 mg). B: Sequence similarity between binding
peptides and rhTNF-a. 31, 33, 34, 38, 39, 310, 312 and 314 represent different binding peptides. All the selected binding peptides were homologous
to the region 80–91aa of rhTNF-a. C: Development of anti-rhTNF-a antibodies using KLH-312.The interaction between rhTNF-a and sera was tested
by ELISA. Results are expressed as OD at 450 nm. Group1: the control group sera immunized with KLH diluted as 1:500; group2–7: sera immunized
with KLH-312 were diluted from 1:500–1:16000. The experiment was performed twice. D: The interaction between rhTNF-a and sera was tested by
Western Blot. The rhTNF-a protein was applied to SDS-PAGE and transferred to the membrane. And the antisera of peptides were added, the antisera
of hTNF-a as the positive control. And the antisera of KLH were taken as the negative control. The antisera are diluted as 1:500. Lane1: antisera against
rhTNF-a; Lane2: antisera against KLH-312; Lane3: antisera against KLH. E: Development of anti rhTNF-a antibodies using KLH-YG1, The interaction
between rhTNF-a and sera was tested by ELISA. Results are expressed as OD value at 450 nm. Group1: control group sera immunized with KLH
diluted as 1:500; Group2–7: sera immunized with KLH-YG1 were diluted from 1:500–1:16000. The experiment was performed twice. F: The interaction
between rhTNF-a and sera was tested by Western Blot. The method was described as figure1D. The antisera are diluted as 1:500. Lane1: antisera
against rhTNF-a; Lane2: antisera against KLH-YG1; Lane3: antisera against KLH.
doi:10.1371/journal.pone.0008920.g001
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hemocyanin (KLH). Antisera against the conjugate were prepared
and were found to exhibit reactivity toward rhTNF-a by
performing ELISA and western blotting (Figure 1C, 1D). This
peptide was predicted to be the mimotope of hTNF-a, and the
homologous region in hTNF-a was assessed as a potential epitope.
Next, the peptide that corresponded to the 80–91 residues of
hTNF-a was synthesized, conjugated to KLH, and used for
vaccination. As expected, the results of ELISA and Western Blot
revealed that the antisera could react with rhTNF-a (Figure 1E,
1F). Our results suggested that this epitope should be a linear
epitope of rhTNF-a.
No Cross-Reactivity between the Epitope and the
Commercial Antibodies
As described above, the commercial antibodies infliximab,
which is a chimeric (75% human and 25% mouse peptide
sequences) monoclonal antibody against hTNF-a and adalimu-
mab, which is the first fully human antibody (100% human
peptide sequences) against hTNF-a have been available thus far.
To analyze whether the epitope identified in our study could react
to these antibodies, the synthetic peptide (10 mg/well) and rhTNF-
a (2 mg/well) were individually coated over the wells of microtiter
plates, respectively, following which the 100 ml monoclonal
antibodies (infliximab, adalimumab, and Z12 at the concentration
of 1 mg/ml) or 100 ml polyclonal anti-hTNF-a antibodies (PA)
with the same concentration with monoclonal antibodies were
added. The results of ELISA revealed that all of the antibodies
could bind hTNFa, while contrasted with PA, the commercial Abs
couldn’t bind the peptide (Figure 2). This result confirmed that
the 80–91 residue of hTNF-a was a novel epitope, and we
designated it as YG1.
Inhibition of the rhTNF-a Cytotoxicity by Antibodies
against YG1
Anti-YG1 Ab was purified by YG1 conjugated Sulfolink
coupling resin (Pierce) according to the manufacture’s instruc-
tion. The rhTNF-a (final concentration 5 pg/ml), with different
dilution of anti-YG1 antibodies, was added to each well. The
actinomycin D was added with final concentration 1 mg/ml. The
plates were incubated at 37uC for 18–24 h incubation in 5%
CO2. The cell viability was measured by MTT assay.
Absorbance was measured at a wavelength of 595 nm to
calculate the percentage of viable cells. The result showed that
anti-YG1 antibodies could statistically inhibit cytotoxicity of
hTNF-a and increase survival of the L929 cells in a dose
dependent manner, compared with the control of normal
antibodies (Figure 3).
YG1 Could Suppress the Development of CIA in an
Animal Model of RA
RA is a chronic and inflammatory disorder characterized by
polyarthritis with progressive joint erosion and dysfunction.
Previous studies suggest that: (1) TNF-a is expressed at high levels
in the inflamed synovium, particularly at the cartilage-pannus
junction of RA patients [11–13]; and (2) TNF-a inhibitors (eg.
infliximib, adalimumab, and etanercept-a recombinant hTNF
receptor (p75)-Fc fusion protein) have been used in the RA
treatment in clinical practice [14,15].
An animal model of CIA, which is a type of polyarthritis with
many histopathologic features similar to those of RA, was
generated. The TNF-a and the region according to YG1 were
highly conserved in human, mice and rats (Figure 4A, 4B). We
attempted to test the function of the newly identified epitope in
such an animal model. Twenty-four rats were separated into 3
groups (A, B, and C, 8 rats each). The rats in group A were
immunized with KLH alone, while those in group B and C were
prevaccinated with KLH-YG1, as described in ‘‘Materials and
methods.’’ The interaction between anti-YG1 sera and rhTNF-a
was tested by performing ELISA. The results revealed that YG1
could induce the production of specific antisera against hTNF-a
(Figure 4C) in rats. Further, the animal in group A and B
received 2 immunizations with bovine collagen type II (CII), and
rats of group C served as controls. From day 12 to 14 after the
primary immunization, swelling was noted in the joints of the 16
rats in groups A and B. The arthritis scores were significantly
lower in the KLH-YG1-treated rats than in the KLH-treated rats
(Figure 4D). The group C rats showed no loss of body weight and
did not develop any skin lesions. These results indicated that YG1
treatment could suppress the development of CIA. Histologic
examination of the joints revealed severe articular cartilage
erosion, bone erosion, massive inflammatory cell infiltration, and
obvious pannus formation in the control group. Moderate or mild
synoviocyte hyperplasia and articular cartilage erosion were noted
in the YG1-KLH-treated rats, and the degree of arthritis was
significantly lower in these rats than in the KLH-treated rats
(2.7561.12 versus 3.1860.85, P,0.05) (Figure 4E, 4F). We also
Figure 2. The interaction between different antibodies and
YG1. The synthesized peptide according to YG1 and rhTNF-a were
individually coated. Different antibodies were added, Infliximab,
Adalimumab and Z12 referred to three monoclonal antibodies, while
PA was the polyclonal antibodies against rhTNF-a. The results were
expressed as OD value at 450 nm. The experiment was performed
twice.
doi:10.1371/journal.pone.0008920.g002
Figure 3. anti-YG1 Ab could inhibit the cytotoxicity of rhTNF-a.
Various concentrations of antibodies against to YG1 and control
antibodies were added to inhibit the cytotoxicity of rhTNF-a. The
cytotoxicity was measured by detecting the amounts of cells by MTT.
Values represent the mean 6 SD for 3 independent tests. * represent
P,0.001(anti-YG compared with normal Ab).
doi:10.1371/journal.pone.0008920.g003
A Novel Epitope of Human TNFa
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8920assessed the cytokine levels (TNF-a and IFN-c) in the blood of the
rats in each group. The results indicated that TNF-a production
was significantly reduced in group B as compared to group A
(Figure 4G); however, no difference was observed between the 2
groups with regard to the blood level of IFN-c (Figure 4H).
Identification of the Key Amino Acids in YG1
Further, we attempted to identify the key amino acids in YG1
by constructing an alanine-scanning library. First, a phage-
displayed 12-mer peptide library, wherein the residues are ideally
allowed to vary only as one of the wild-type amino acids or
alanine, was constructed on the basis of the YG1 sequence
(Table 1), although the nature of the genetic code necessitates 2
other amino acids substitutions for some residues. Twenty clones
were randomly selected and sequenced; the results revealed that
the distribution of nucleotides at each position was almost identical
with the expected frequency (data not shown). The original
transformants were 4.0610
4, and the theoretical deviation of the
library was 1.6610
4, so the constructed library should consist of all
mutagenic oligonucleotide. The peptides in the library that were
specifically bound to the anti-TNF-a antibodies were subsequently
selected and sequenced (Figure 5A). With sequence analysis, 7
conserved amino acids in the selected sequences were identified
(Figure 5B). The sequence alignment between the mimotope and
rhTNF-a (Figure 1B) suggested that alanine might not have been
the key residue in the epitope. The fact that alanine was identified
as one of the conserved amino acids may be a limitation of this
method because alanine in YG1 could not be replaced in the
alanine-scanning library. An artificial peptide (AP), wherein the
residues other than the key amino acids were replaced with
alanine, was synthesized and coupled with KLH. Mice were then
vaccinated with this complex for the production of polyclonal
antibodies. The results of ELISA and Western Blot revealed that
the antisera could specifically bind to rhTNF-a (Figure 5C, 5D).
Thus, we concluded that the selected residues were sufficient to
induce the production of anti-TNF-a antibodies.
Figure 4. YG1 could suppress the development of collagen-induced arthritis in the Rheumatoid arthritis animal model. A: The
homology analysis of TNF-a in human, mice and rats. B: The homology analysis of the region of TNF-a according to YG1 in human, mice and rats. C:
The detection of antisera against rhTNF-a in rats. Rats in Group A were prevaccinated with KLH, while Rats in Group B and C were prevaccinated with
KLH-YG1. The sera were diluted as 1:100, and the interaction between rhTNF-a and sera was tested by ELISA. D: Arthritis score. KLH represents the
rats of Group A immunizied with CII, and KLH-YG1 represents the rats of Group B immunizied with CII. E: Histologic analysis of ankle joints in CIA rats.
Normal represents the normal rats, KLH represents the rats Group A immunizied with CII, and KLH-YG1 represents Group B immunizied with CII
(Original magnification 610). F: Histologic score of ankle joints in CIA rats. KLH represents the rats Group A immunizied with CII, and KLH-YG1
represents Group B immunizied with CII. G, H: Detection the concentration of different cytokines in blood. The production of TNF-a and IFN-c was
analyzed in the different groups.
doi:10.1371/journal.pone.0008920.g004
A Novel Epitope of Human TNFa
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8920On the basis of the key residues, 6 rhTNF-a mutants (T1,
R82A; T2, T83A; T3, P84A; T4, D86A; T5, P88A; and T6,
V89A) were expressed and purified, as described in ‘‘Materials and
methods’’. We then tested the binding between the mutants and
the anti-YG1 sera. The results of ELISA demonstrated that the
anti-YG1 sera could not recognize the two rhTNF-a mutants
P88A and V89A (Figure 5E). These results suggested that the
residues Proline and Valine were the most critical amino acids in
YG1. Further, we tested the activities of the abovementioned
mutants by assessing the TNF-a-induced cytotoxicity. The results
revealed that the two mutants P88A and V89A was significantly
less cytotoxic than wild-type rhTNF-a (Figure 5F) and that the
two abovementioned key amino acids in YG1 were also important
for the biological functions of TNF-a.
Discussion
One of the critical findings is that proinflammatory cytokines
such as TNF-a were present in the synovium and plasma of
patients with RA. It has thrown new light on the attempts to
develop RA therapies since 1980s [11–13]. Despite of the
potential adverse effects and limitations, the licensed anti-TNF-a
monoclonal Abs, adalimumab and infliximab, have proved to be
remarkably successful as an injectable protein-based therapy in
clinical treatment of immune-mediated inflammatory diseases
(IMID), such as rheumatoid arthritis (RA), Crohn’s disease,
inflammatory bowel disease (IBD), psoriatic arthritis (PsA), and
ankylosing spondylitis(AS) [16]. Intriguingly, the precise mech-
anisms, by which infliximab and adalimumab work, are in part
different, such as effects of TNF-a blockade on reverse (outside to
inside) intracellular signaling cascade, infiltrating cells, epithelial
cells’ barrier function [17]. It probably explains why there are
some differences in the indications of the two monoclonal Abs.
For example, infliximab approved to be applied on ulcerative
colitis patients, while adalimumab is lack of efficacy in such
disease. It’s also comprehensible that some RA patients
intolerant of one of the Abs could switch to the other, which
w o u l db es a f ea n de f f e c t i v e[ 1 8 ] .T h o s er e s u l t ss u g g e s t e dt h et w o
Abs would bind the different sites of TNF-a.S ow ew o n d e r
whether there are some other epitopes of hTNF-a for developing
novel therapeutic antibodies.
In this work, we tried to obtain the epitopes by biopanning
phage-displayed peptide library against anti-hTNF-a polyclonal
Abs. The positive phage clones identified by ELISA assay
exhibited 8 different sequences, in which there was one similar
sequence embedded in hTNF-a(80-91aa). The antisera raised
against the selected peptide 312 or the peptide YG1 of hTNF-
a(80–91aa) had the specific reactivity with rhTNF-a, which
suggested that both the mimotopes of hTNF-a and the
corresponding epitope exhibited similar immunogenicity. The
key amino acids of an epitope usually comprise 3,5 residues, so
we identified the key ones in YG1 by means of alanine-scanning
and site-directed mutation. Proline and Valine proved to be the
most important amino acids in YG1.
It was found that the epitope peptide YG1 could not be
recognized by the marketed Abs, so it suggested that YG1 was a
novel epitope of hTNF-a. The biological function of YG1 was
elucidated in rat model of CIA. The progress of CIA is associated
with the level of TNF-a, while the rats vaccinated with YG1
showed less severity of inflammatory reaction, contrasted with the
control. We also indentified that the antibodies against YG1 could
efficiently inhibit the cell toxicity induced by hTNF-a. The epitope
YG1 is not located at the receptor-binding site (150–155 residues)
of hTNF-a [19], so the antibodies against YG1 might not directly
inhibit the binding hTNF-a and receptor. The mechanism how
the antibodies of YG1 inhibit the function of hTNF-a may be
different from the present antibodies and still remains unclear. We
tried to construct the theoretical 3-D trimer structure of TNF and
2 mutants (P88A and V89A) on the basis of the 3-D crystal
structure of TNF (PDB code: 1tnf). The preliminary data showed
that it was more difficult for T5 and T6 to form trimer than for
wild types (data not shown). The further mechanism is being
addressed in our lab. However, our results suggested that there
should be other sites (including YG1) at hTNF-a for novel
antagonists development.
Our work also reveals that combination of phage display and
alanine-scanning is an efficient way to identify the novel precise
epitopes in a disease-related molecule. It will be useful for
development and optimization of corresponding targeting therapy.
Materials and Methods
Ethics Statement
All animal experimental protocols of the study are in
accordance with the national guidelines for the use of animals in
scientific research. It’s also approved by Animal Care and Use
Committee of the Peking University People’s Hospital.
Antibodies
Infliximab, adalimumab, and Z12 were kindly provided by
Professor Yan Li (Beijing Institute of Basic Medical Sciences). Z12
is a monoclonal antibody developed in the laboratory of Professor
Yan Li and contains a distinct epitope; its structure is comparable
to those of the 2 commercial antibodies (unpublished data).
Phage Display Peptide Library, Bacterial Strains, and
Animals
The Ph.D.-12
TM phage display peptide library kit was
purchased from New England Biolabs (Beverly, MA, USA). The
complexity of the library was 1.9610
9, and the titer was
1.5610
13 pfu/ml. The E. coli strain ER2537 was used as the host
strain for the phage library. The Ph.D.
TM Peptide Display Cloning
System was also purchased from New England Biolabs. The E. coli
Table 1. The shotgun scanning code.
Amino acid Shotgun codon* Shotgun substitutions
S KCT A/S
R RSG A/G/T/R
T RCT A/T
P SCT A/P
S KCT A/S
D GMT A/D
K RMG A/E/T/K
P SCT A/P
V GYT A/V
A GCT A
H SMT A/D/P/H
For each amino acid, the appropriate shotgun codon ideally encodes only the
wild-type amino acid or alanine, but the nature of the genetic code necessitates
the occurrence of 2 other amino acids for some shotgun substitutions. Single-
letter amino acid and nucleotide abbreviations are used.
*DNA degeneracies are represented by the IUB code (K=G/T, M=A/C, N=A/C/
G/T, R=A/G, S=G/C, W=A/T, Y=C/T).
doi:10.1371/journal.pone.0008920.t001
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white rabbits and outbred male BALB/c mice (weight, 20–25 g)
were provided by Beijing Research Center of Animals. Inbred
female Lewis rats were purchased from Laboratory Animal
Resource Center of Peking University Medical Science Center.
The rats were housed in a specific pathogen-free environment and
were provided standard rodent chow diet ad libitum.
Production and Purification of Polyclonal Anti-
Recombinant Human TNF-a Antibodies
Purified recombinant human TNF-a (rhTNF-a) was produced
as described previously [20]. Female New Zealand White rabbits
were first immunized by subcutaneously injecting them with 1 ml
of the immunogen (1 mg of rhTNF-a in phosphate-buffered saline
(PBS) mixed with complete Freund’s adjuvant (Sigma)). Subse-
quent booster injections, i.e., 1 mg of rhTNF-a in PBS emulsified
in incomplete Freund’s adjuvant (Sigma), were administered at 3
and 6 weeks after the primary immunization. At the eighth week,
the sera were collected and the antibody titers were determined by
ELISA. Anti-rhTNF-a antibodies were purified on an immuno-
affinity column which was prepared by conjugating purified
rhTNF-a to carboxylated acrylonitrile butadiene (CNBr)-activated
Sepharose
TM 4B resin (Amersham Biosciences), according to the
manufacturer’s instructions.
Selection of Peptides Binding to rhTNF-a Antibodies by
Phage Display
The selection procedure was in accordance with the protocol
provided with the Ph.D.-12 peptide library kit (New England
Biolabs). For each selection cycle, 1610
11 phages were applied to a
96-well plate precoated with anti-rhTNF-a antibodies (10 mg/well).
The level of specific phage enrichment was calculated as the input-
output ratio, as described previously [21]. After 3 rounds of
biopanning, the positive phage clones were selected and sequenced.
Figure 5. Identification of key amino acid in YG1. A: Specific phage clones binding to rhTNF-a antibodies were selected by ELISA and
competitive ELISA. 1–8 referred to different phage clones. White bars represent negative control, black bars represent screened phage clones (1610
9)
alone, and gray bars represent screened phage clones (1610
9) plus rhTNF-a protein (5 mg). B: Sequence similarity between binding peptides
obtained by Alanine Scanning and the N terminus of rhTNF-a. The alignment of different sequences was proceeded by the software DNAMAN. 1–7
referred to different binding peptides sequences. The conserved sequence is XXRTPXDXPVAX (X means any amino acid). C: Development of anti-
rhTNF-a antibodies using KLH-AP. The interaction between rhTNF-a and sera was tested by ELISA. Results are expressed as OD value at 450 nm.
Group1 represents control group sera immunized with KLH, Group2–7 represent sera immunized with KLH-AP were diluted from 1:500–1:16000. D:
The interaction between rhTNF-a and sera was tested by Western blot. Different antisera was diluted as 1:500. Lane1 represents antisera against
rhTNF-a, and Lane2 represents antisera against KLH-AP, Lane3 represents antisera against KLH. E: The interaction between different rhTNF-a mutants
and sera immunized with KLH-YG1 was tested by ELISA. The result of ELSIA was expressed as OD at 450 nm. T1, R82A; T2, T83A; T3, P84A; T4, D86A;
T5, P88A and T6, V89A. The experiment was performed twice. F: Detection of the cytotoxicity induced by rhTNF-a and mutants. Serial dilutions of
rhTNF-a and mutants (T5, T6) were incubated with L929 cells. The cytotoxicity was measured by detecting the amounts of cells by MTT (the triangle
bar: wild type, the diamond bar:T5, the square bar: T6). The experiment was performed twice.
doi:10.1371/journal.pone.0008920.g005
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The specific binding of the positive phage clones to the
polyclonal anti-rhTNF-a antibodies was tested by performing
ELISA. In brief, the 96-well plates (Nunc) were coated with
anti-rhTNF-a polyclonal antibodies (10 mg/well) overnight at
4uC. The unbound antibodies were discarded, and the wells
were blocked with 3% bovine serum albumin in PBS at 37uCf o r
1 h. The selected phage clones (1610
9 pfu/well) were added to
the wells in duplicate, and the plates were incubated at 37uCf o r
2 h. The plates were then washed 5 times with PBS-0.05%
Tween-20, following which a horseradish peroxidase (HRP)-
conjugated anti-M13 polyclonal antibody (1:1000), (Amersham
Biosciences) was added, and the plates were incubated at 37uC
for 1 h. After the plates were washed as described above, the
bound antibodies were detected using 3,39,5,59-tetramethyl-
benzidine dihydrochloride (Sigma, St. Louis, USA) as the
substrate, and the color intensity was determined spectropho-
tometrically at 450 nm.
Western Blot
rhTNF-a protein (2 mg) was subjected to 15% SDS-PAGE, then
blotted onto Hybond-ECL nitrocellulose membrane (Amersham
Biosciences) for 30 min at 20 V. After blocking for 2 h at 37uCi n
5% non-fat milk, the membrane was probed with various antisera
(1:500), diluted in blocking buffer for 1 hr at room temperature,
and washed twice with 0.5% PBST. Then the membrane was
incubated in a goat anti-rabbit HRP-conjugated secondary
antibody (1:2,000), diluted in blocking buffer, and washed four
times with 0.5% PBST. The binding of rhTNF-a with
corresponding antibodies was detected by the enhanced chemilu-
minescence (ECL) Western blotting detection system.
Competitive ELISA
Various concentrations of the rhTNF-a protein along with
1610
9 phage particles were added into each well of the 96-well
plates (Nunc); the wells were precoated with anti-rhTNF-a
antibodies. The bound phages were detected as described above
using HRP-conjugated anti-M13 polyclonal antibody.
Induction of CIA and Evaluation of Its Clinical Severity
Five-week-old Lewis rats were prevaccinated with KLH-YG1
or KLH. The rats were first immunized by subcutaneously
injecting them with 0.5 ml of the immunogen (0.5 mg of KLH-
YG1 or KLH in PBS mixed with complete Freund’s adjuvant).
Subsequentbooster injections, comprising 0.25 mg of KLH-YG1
or KLH in PBS emulsified in incomplete Freund’s adjuvant
(IFA), were administered 1 week after the primary immunization.
The prevaccinated rats were then immunized with bovine CII
(Sigma) as described previously [22,23]. Briefly, bovine CII was
dissolved in 0.1 M acetic acid at a concentration of 4 mg/ml and
emulsified in an equal volume of IFA (Sigma). The rats were
immunized intradermally by injecting them at the base of the tail
with 150 ml of the emulsion (containing 300 mgo fC I I )o nd a y s0
and 7. The incidence and severity of induced arthritis were
determined by assessing the weight loss and scoring each paw on
the basis of the degree of swelling, erythema, and deformity in the
joints [11]. The arthritic lesions were scored on a scale of 0–4,
where a score of 0 corresponded to no change; 1, swelling and
erythema of the digit; 2, mild swelling and erythema of the limb;
3, gross swelling and erythema of the limb; and 4, gross deformity
and inability to use the limb. The arthritis score recorded for
each rat was the sum of the scores of the individual paws; the
maximum score was 16.
Histopathological Analysis
The hind paws of the rats in different groups were dissected,
fixed in 10% neutral buffered formalin for 48 h, and decalcified in
10% (w/v) ethylenediaminetetraacetic acid disodium salt (EDTA-
2Na) until the bones were pliable. The tissues were then
dehydrated in an alcohol gradient, embedded in paraffin, cut into
4-mm thick sections, and stained with hematoxylin and eosin. The
sections were analyzed microscopically to observe the degree of
inflammation and cartilage and bone destruction, according to a
previously reported method [24]. The following scale was used to
assess this degree: 0, normal synovium; 1, synovial membrane
hypertrophy and cell infiltration; 2, pannus and cartilage erosion;
3, major erosion of the cartilage and subchondral bone; and 4, loss
of joint integrity and ankylosis.
Analysis of Cytokine Production
Blood samples were collected on day 35 after the primary
immunization. The serum levels of TNF-a (Dakewei Biotech
Company Ltd., China) and IFN-c (Jingmei, China) were measured
using commercially available ELISA kits according to the
manufacturer’s instructions.
Construction of the Alanine-Scanning Library
The libraries were constructed using the M13KE gIII cloning
system (NEB). A template oligonucleotide with the sequence 59-
CATGTTTCGGCCGAAKSAGCAR-CAGSCKYAKCAGMA-
GSAGYCSYAGMAGMAGAGTGAGAATAGAAAGGTACCC-
GGG-39 (DNA degeneracies are represented by the International
Union of Biochemistry (IUB) code (K, G/T; M, A/C; N, A/C/G/
T; R, A/G; S, G/C; W, A/T; Y, C/T)), which contained the
fragment encoding the insert sequence of hTNF-a (80–91) or Ala-
mutated sequences, was annealed to the extension primer. This
template was then extended using DNA polymerase, large
(Klenow) fragment (NEB) and converted into the double-stranded
form. The double-stranded DNA was digested with Acc65 I and
Eag I to release an internal 60-bp fragment. This fragment was
purified by 12% polyacrylamide gel electrophoresis in Tris–
borate–EDTA (TBE) and was eluted with a buffer containing
0.5 M ammonium acetate (NH4Ac), 10 mM magnesium acetate
(Mg (Ac)2), and 1 mM EDTA. The eluate was purified and
concentrated by ethanol precipitation. The purified fragment was
ligated into the M13KE vector that was double-digested with
Acc65 I and Eag I. The ligation product was transfected into
competent ER2537 cells by 10 sessions of electroporation. The
transformation mixture was grown in a 200 ml suspension of cells
early-log phase in Luria-Bertani (LB) medium for 4.5 h. The
phage was purified according to the manufacturer’s instructions.
Meanwhile, 20 original transformants were randomly selected for
sequencing. Furthermore, the constructed alanine-scanning library
was screened with anti-rhTNF-a antibodies for three rounds.
Expression and Purification of Recombinant hTNF-a and
the Site-Specific Mutants
rhTNF-a and its mutants were expressed in E. coli by using the
conventional methods. In brief, the genes coding rhTNF-a and its
mutants were amplified by polymerase chain reaction (PCR) using
the template DNA pUC-rhTNF-a vector (stored in our lab) with
the individual forward primers(wild type(WT): GGGAATTC-
CATATGGTACGTTCTTCTTCTCGTACTCCGAGTGACA-
AGCCTGTAGCCCATGTTGTAG, R82A (T1): GGGAATT-
CCATATGGTACGTTCTTCTTCT gcTACTCCGAGTGAC-
AAGCCTGTAGCCCATGTTGTAG, T83A(T2):GGGAAT T-
CCATATGGTACGTTCTTCTTCTCGTgCTCCGAGTGACAA-
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CATATGGTACGTTCTTCTTCTCGTACTgCGAGTGACA-
AGCCTGTAGCCCATGTTGTAG, D86A (T4):GGGAATTC-
CA TATGGTACGTTCTTCTTCTCGTACTCCGAGTGcCA-
AGCCTGTAGCCCATGTTGTAG, P88A (T5): GGGAATT-
CCATATGGTACGTTCTTCTTCTCGTACTCCGA GTGA-
CAAGgCTGTAGCCCATGTTGTAG, V89A (T6): GGGAAT-
TCCATATGGT ACGTTCTTCTTCTCGTACTCCGAGTG-
ACAAGCCTGcAGCCCATGTTGTAG, the lowercased and
italicized letters indicate the mutation sites, and the underlined
sequences indicate NdeI recognition sites) and the same reverse
primer(CCGCTCGAGTCACAGGG CAATGATCCCAA, the
underlined sequences indicate XhoI recognition sites). The
amplified fragments were digested with NdeI and XhoI and inserted
into the corresponding sites in the pET-28a vector (Novagen)
sequence. Recombinant protein expression was induced by adding
isopropyl b-d-thiogalactopyranoside (IPTG) (0.1 mM) to the
growing culture at an optical density of 0.4 at 600 nm (OD600).
The recombinant protein was purified on a Ni Sepharose
TM 6 Fast
Flow column (Amersham Biosciences), according to the manufac-
turer’s instructions.
Detection of the Cytotoxicity Induced by rhTNF-a and Its
Mutants
In brief, L929 (4610
4 cells/ml, 100 ml/well) were seeded in 96-
well microtiter plates (Costar). They were then cultured overnight
at 37uC in complete Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) containing 10% fetal bovine serum (Hyclone),
in the presence of 5% CO2. The rhTNF-a and mutants were
serially diluted. Further, 20 ml of each dilution along with 5 ml
actinomycin D (25 mg/ml) was added to each well, and the plates
were incubated at 37uC for 18–24 h incubation in 5% CO2. The
cell viability was measured by performing a standard 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
(MTT). Absorbance was measured at a wavelength of 595 nm
to calculate the percentage of viable cells.
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